NOVOCURE LTD (NVCR)

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Commit To Buy NovoCure At $7.50, Earn 15.3% Using Options

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Novocure to Report First Quarter 2024 Financial Results

Why NovoCure Stock Soared 18.3% This Week

Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.

Why Novocure Stock Is Jumping Today

Novocure had good news mixed with some not-so-good news.

Noteworthy Wednesday Option Activity: NVCR, JEF, JPM

Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment

The company uses electrical fields to interrupt the rampant cellular division characteristic of cancer.

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

NovoCure (NVCR) Q4 2023 Earnings Call Transcript

NVCR earnings call for the period ending December 31, 2023.

NovoCure GAAP EPS of -$0.45 beats by $0.07, revenue of $133.78M in-line (NASDAQ:NVCR)

NovoCure reported Q4 2023 financial results, beating expectations with a GAAP EPS of -$0.45.

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Notable Wednesday Option Activity: CLF, BYON, NVCR

Notable Thursday Option Activity: NVCR, VLO, NEM

NovoCure stock rises as FDA reviews Tumor Treating Fields (NASDAQ:NVCR)

Novocure (NVCR) stock gains as its marketingapplication for its cancer treatment, Tumor Treating Fields (TTF), has been accepted by the FDA. Read more here.

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Commit To Buy NovoCure At $12.50, Earn 24.8% Using Options

Novocure reports better-than-expected preliminary Q4, FY revenue (NASDAQ:NVCR)

Novocure reports preliminary 2023 net revenues of $509M and Q4 net revenues of $134M, with a decrease in full-year revenue compared to the prior year.

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

Novocure appoints Nicolas Leupin as its chief medical officer (NASDAQ:NVCR)

Novocure names Nicolas Leupin as its new Chief Medical Officer.

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

NovoCure stock gains on J.P. Morgan event (NASDAQ:NVCR)

Novocure's (NVCR) stock adds 12% as the company confirms its participation at the J.P. Morgan Healthcare Conference next month. Read more here.

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

7 Nasdaq Stocks Down 59% Set to Soar at Least 141%

Wall Street always think companies are high-growth potential stocks but a little circumspection is required before buying

FCEL Stock Alert: FuelCell Energy Announces AI Deal With IBM

FuelCell Energy stock is climbing higher on Tuesday as investors in FCEL celebrate the company signing a deal with IBM!